Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Posted by Karen Goldfarb
March 28, 2023 at 4:41 PM
Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
March 20, 2023 at 7:13 PM
An updated Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 98-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia
Posted by Karen Goldfarb
January 24, 2023 at 3:17 PM
An Executive Informational Overview (EIO) is now available on Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies, primarily for rare and orphan diseases, with an initial focus on Sickle Cell Disease (SCD). The 76-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: orphan diseases, EMMA, orphan drug, sickle cell crisis, The Steve Harvey Show, emmaus life sciences, sickle cell disease, L-glutamine, endari, diverticulosis
Posted by Karen Goldfarb
December 21, 2022 at 2:30 PM
A 13-page Quarterly Update is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases.
Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin
Posted by Karen Goldfarb
November 11, 2022 at 4:11 PM
Crystal Research Associates has issued a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
Posted by Karen Goldfarb
September 14, 2022 at 8:29 PM
An Executive Informational Overview (EIO) is now available on SG Blocks, Inc., a leading developer, designer, and fabricator of modular structures, meeting the growing demand for safe and green construction. The 64-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: SG Blocks, modular construction, green building, COVID-19 testing, Starbucks, Taco Bell, Sanitec, green construction, shipping containers, GreenSteel, cargo modified modules, Verizon, Puma, Lacoste, NBA, Equinox, Clarity Lab Solutions, SGBX
An Executive Informational Overview (EIO) is now available on Bioxytran, Inc., a clinical stage pharmaceutical company developing therapeutics in two areas: (1) glycovirology and anti-viral therapeutics; and (2) hypoxic conditions, necrosis, and degenerative diseases. The 70-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Topics: covid19, coronovirus, SARS-CoV-2, galectrin-3, glycovirology, bioxytran, complex carbohydrate chemistry, galectin
Posted by Karen Goldfarb
August 5, 2022 at 4:02 PM
Crystal Research Associates has issued a 19-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19, monkeypox
An Executive Informational Overview (EIO) is now available on Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The 62-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: cancer, REQORSA, genprex, diabetes, gene therapy, non-small cell lung cancer, small-cell lung cancer
Posted by Karen Goldfarb
May 18, 2022 at 11:06 AM
An Executive Informational Overview (EIO) is now available on ImmunoPrecise Antibodies Ltd, a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, Oncology, Biologics, Humanized monoclonal antibodies, Immunoassay, Immunogen, Monoclonal antibody, Antibody, Contract research organization (CRO), Customer relationship management (CRM), Human monoclonal antibodies, SARS-CoV-2, Polyclonal antibody, Contract manufacturing organization (CMO), Enterprise resource planning (ERP)
Posted by Karen Goldfarb
April 29, 2022 at 1:23 PM
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19
Posted by Karen Goldfarb
March 14, 2022 at 6:22 PM
Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, cancer, covid19, coronovirus, covid-19
Posted by Karen Goldfarb
March 10, 2022 at 12:14 PM
An Executive Informational Overview (EIO) is now available on FSD Pharma Inc., a biopharmaceutical company focused on developing innovative therapies for brain and inflammatory disorders to improve patient quality of life. The 58-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, multiple sclerosis, inflammatory, MS, major depressive disorder (MDD), myelin degradation, bipilar disorder
Posted by Karen Goldfarb
January 13, 2022 at 12:01 PM
An Executive Informational Overview (EIO) is now available on Victory Square Technologies Inc., a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6), and the OTCQX (VSQTF). The Company builds, acquires, and invests in promising startups, then provides the senior leadership with resources in which to fast-track a company’s growth, resulting in rapid scale-up and monetization. Victory Square’s sweet spot is the innovative technology that is shaping the Fourth Industrial Revolution, where boundaries are being blurred between the physical, digital, and biological worlds. The 76-page report details the Company's business and key sectors of focus, profiles its 20+ investees, as well as details its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: artificial intelligence (AI), Augmented reality, Electronic medical records, Fourth Industrial Revolution, Internet of Things, Metaverse, Non-fungible tokens, Web 3.0, Victory Square Technologies, Creator Economy, Software-as-a-Service, Saas, Solar photovoltaic, Unicorn company, Virtual reality
Posted by Karen Goldfarb
November 30, 2021 at 6:22 PM
An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.
Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, fibrotic, multiple sclerosis, Huntingtons Disease, cannabigerol, SSc, inflammatory, systemic sclerosis, MS, Parkinsons Disease, cannabinoids, cannabidiol
We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.
CONTACT INFORMATION
Phone: (212) 851-6685